Skylark Bio
PrivateLast Round
Series A
May 6, 2024
Total Funding Raised
$60M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Skylark Bio is a biotechnology company that develops targeted gene therapies aimed at addressing the underlying genetic causes of hearing impairment to improve patient outcomes and quality of life.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Skylark Bio Comparables
Compare Skylark Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sensorion SA | 78% | |
| Regeneron Pharmaceuticals | 76% | |
| Eli Lilly and Company | 74% |
Skylark Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 6, 2024 |
Skylark Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ARCH Venture Partners | Series A |
| ARCH Venture Partners | Series A |
| Arkin Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 38% MoM.
- May 6, 2024
$60M round led by ARCH Venture Partners
Recent news
Latest coverage and updates
- launchesSep 24, 2026
Skylark Bio launches SKY-AS.
- attends_eventSep 24, 2026
Skylark Bio plans to present during the Innovations Spotlight: Emerging Track at the 2026 Alliance for Regenerative Medicine (ARM) Meeting on the Mesa in Arizona on Oct 6th '26, showcasing its precision genetic medicine platform and pipeline, including SKY-AS.
- hiresSep 24, 2026
On Sep 28th '26, Dr Edwin Weeber joins Skylark Bio as Scientific Advisor to support SKY-AS development and its broadening CNS pipeline.
- is_developingAug 12, 2026
Skylark Bio is developing gene therapies targeting SLC26A4-related hearing loss alongside investigational programmes in the central nervous system.
- is_developingAug 12, 2026
Skylark Bio is developing a gene therapy targeting GJB2-related deafness and has started an early-stage clinical trial to test it.
Skylark Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Skylark Bio's valuation, stock price, and market status.
Is Skylark Bio a public or private company?
Skylark Bio is a private company.
What is the current stock price of Skylark Bio?
Skylark Bio is a private company, so its shares have no public market price. Caplight tracks Skylark Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Skylark Bio worth (valuation)?
Valuation information for Skylark Bio is not publicly available.
Can I buy Skylark Bio stock?
Skylark Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Skylark Bio's last funding round?
Skylark Bio's most recent funding round was Series A on May 6, 2024.
Who are the main investors in Skylark Bio?
Key investors in Skylark Bio include ARCH Venture Partners, ARCH Venture Partners.
Will Skylark Bio IPO soon?
No public IPO plans have been announced for Skylark Bio.
How can I track Skylark Bio secondary market activity?
Caplight tracks bids, offers, and trades in Skylark Bio's shares on secondary markets.